NCT00815594

Bleb Vascularity Change After Subconjunctival Injection Bevacizumab

Bleb Vascularity Change After Subconjunctival Injection of Bevacizumab

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Capital Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The occurrence of conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery. Vascular endothelial growth factor is thought to be a key role in the formation of conjunctival scar, which play a pivotal role in the wound-healing process. So it seems that the recombinant human anti-VEGF antibody could inhibit angiogenesis, and reduce the conjunctival vascular formation in the wound-healing process after glaucoma filtering surgery.

Conditions

• Bleb Vascularity
• Conjunctival Scarring

Interventions

Type	Name	Description
DRUG	bevacizumab	0.05ml, 1.25mg

Timeline

• Start date: 2008-12-01
• Primary completion: 2009-03-01
• Completion: 2009-05-01
• First posted: 2008-12-30
• Last updated: 2008-12-30

Locations

1 site across 1 country: China